Albany leaders talk rolling back nightclub hours
Committee also hears update on other safety measures
Albany leaders talk rolling back nightclub hours By Bobby Poitevint | January 14, 2021 at 10:24 PM EST - Updated January 15 at 12:03 AM
ALBANY, Ga. (WALB) - Albany leaders talked about reducing night club hours and other security tactics to reduce overnight crimes at a Thursday City of Albany Public Safety Meeting.
Currently, you have to be out of Albany night clubs by 4 a.m., Tuesday through Sunday, according to Albany leaders.
City of Albany Public Safety Committee members have a new idea.
“Alcohol not being served passed 2:45 a.m. and then the businesses close, turn the lights off and go home at 3:15 a.m.,” Chad Warbington, committee chair and Albany city commissioner, said.
Steven Runk, Lewis Center for the Arts
Jan. 19, 2021 5:33 p.m.
Roger S. Berlind, a member of Princeton’s Class of 1952, former University trustee, Tony Award-winning producer, and a supporter of the arts and humanities at Princeton, died of cardiopulmonary arrest Dec. 18 at his home in Manhattan. He was 90.
Roger S. Berlind
Photo by Kah Leong Poon
“It is with great sorrow and intense gratitude that we honor the life and legacy of Roger S. Berlind,” said Tracy K. Smith, chair of the Lewis Center for the Arts and the Roger S. Berlind ’52 Professor in the Humanities. “Roger s visionary spirit, deep altruism, and abiding generosity have made possible decades worth of art and creation at Princeton. He was also affable and witty. His energy was galvanizing to all of us who had the pleasure to meet him.”
Yaqrit Discovery Ltd: Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure
Orally-administered,
non-absorbable engineered carbon, Carbalive
, was safe, tolerable and showed trends in improvements in a range of biomarkers of systemic inflammation associated with decompensated cirrhosis
Safety of novel dual filtration system, Dialive
, confirmed with liver failure patients more likely to see organ failure resolved and more quickly than control group
London, UK, 7 January 2021 - Yaqrit, a clinical stage life sciences company focused on developing potentially innovative treatments for patients with advanced liver disease in areas of high unmet medical need, today announces preliminary results from its randomised controlled clinical trials for two potential therapies from its pipeline of product candidates designed to address each stage of liver disease, from diagnosis of decompensated c
Yaqrit Discovery Ltd
Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure
Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure
Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure
Orally-administered,
non-absorbable engineered carbon, Carbalive
™, was safe, tolerable and showed trends in improvements in a range of biomarkers of systemic inflammation associated with decompensated cirrhosis
Safety of novel dual filtration system, Dialive
™, confirmed with liver failure patients more likely to see organ failure resolved and more quickly than control group
The ALIVER Consortium announces positive results from Phase 2 equivalent trial of the novel liver dialysis device, Dialive
Safety of novel liver dialysis device confirmed
Liver failure patients in ICU treated with Dialive more likely to see organ failure resolved, and more quickly (p=0.03)
Significant improvements in mechanistic biomarkers of how Dialive improves organ function
7
th January 2021 - The
ALIVER Consortiumis pleased to announce positive data from the randomised controlled clinical trial of Dialive in adult patients with liver failure. The study found that twice as many patients with a history indicative of alcohol-related cirrhosis suffering from multiorgan failure, a condition referred to as acute-on-chronic liver failure (ACLF), recovered to having no organ failure when treated with the Dialive device compared to the control group.